EMILY SHETTY

Issues pertaining to access to quality care for blood cancer patients [HR 460, the Patients Access to Treatments Act - all provisions]; [HR 2827, the Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to network adequacy].

Issues pertaining to access to quality care for blood cancer patients [HR 460, the Patients Access to Treatments Act - all provisions]; [HR 1801, the Cancer Drug Coverage Parity Act - all provisions]; [S 1365/HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care - provisions specific to network adequacy and cost sharing]; [S. 2115, the American CURES Act - all provisions]; Energy & Commerce committee proposal re: FDA reform

Issues pertaining to access to quality care for blood cancer patients [HR 460, the Patients Access to Treatments Act - all provisions]; [HR 1801, the Cancer Drug Coverage Parity Act - all provisions]; [S 1365/HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care - provisions specific to network adequacy and cost sharing]; [S. 2115, the American CURES Act - all provisions]; Energy & Commerce committee proposal re: FDA reform

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]

Issues pertaining to the FDA drug approval process and agency funding - [HR 2725, the FDA Safety Over Sequestration Act]; Issues pertaining to funding for the National Center for the Advancement of Translational Sciences and the National Institutes of Health, specifically for pediatric and general cancer research - [FY14 Labor Health and Human Services and Related Agencies subcommittee bill - provisions related to NCATS & NIH]

Issues pertaining to the FDA drug approval process and agency funding - [FY14 Agriculture, Rural Development, Food and Drug Administration and Related Agencies subcommittee bill]; [HR 2725, the FDA Safety Over Sequestration Act]; Issues pertaining to funding for the National Center for the Advancement of Translational Sciences and the National Institutes of Health, specifically for pediatric and general cancer reserch - [FY14 Labor Health and Human Services and Related Agencies subcommittee bill - provisionsrelated to NCATS & NIH]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [The Cancer Drug Coverage Parity Act - all provisions]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 2827, The Part D Beneficiary Appeals Fairness Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to Medicaid and end of life issues]

Issues pertaining to access to quality care for blood cancer patients [HR 460, Patients Access to Treatments Act - all provisions]; [HR 1801, The Cancer Drug Coverage Parity Act - all provisions]; [HR 1239, Accessing Medicare Therapies Act - all provisions]; [P.L. 111-148, the Patient Protection and Affordable Care Act - provisions specific to implementation efforts of the Health Insurance Exchanges]; Issues pertaining to access to innovative therapies for blood cancer patients [P.L. 112-144 - The Food andDrug Administration Safety and Innovation Act - provisions specific to expedited access to new therapies]; Issues pertaining to federal funding for pediatric research [HR 2019, Kids First Research Act - provisions specific to NIH funding for pediatric research]; Issues pertaining to survivorship for childhood cancer patients and survivors [HR 2607, Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act - all provisions]